https://www.medscape.com/viewarticle/nice-u-turn-expands-access-prostate-cancer-drug-2025a1000tph
In a significant policy reversal, the National Institute for Health and Care Excellence (NICE) has recommended abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, following a reassessment prompted by the availability of lower-cost generic versions.
No hay comentarios:
Publicar un comentario